tetano
Editor, Senior Moderator
Virol J
. 2024 Oct 28;21(1):266.
doi: 10.1186/s12985-024-02523-7. Metabolomic alterations in the plasma of patients with various clinical manifestations of COVID-19
Qi Xin[SUP] #[/SUP][SUP] 1 [/SUP], Xiao Liang[SUP] #[/SUP][SUP] 1 2 [/SUP], Jin Yang[SUP] 1 2 3 [/SUP], Xiaorui Wang[SUP] 1 [/SUP], Fang Hu[SUP] 1 [/SUP], Meng Jiang[SUP] 1 [/SUP], Yijia Liu[SUP] 1 [/SUP], Jin Gong[SUP] 1 2 [/SUP], Yiwen Pan[SUP] 1 [/SUP], Lijuan Liu[SUP] 1 [/SUP], Jiao Xu[SUP] 1 [/SUP], Yuxin Cui[SUP] 1 [/SUP], Hongyu Qin[SUP] 1 [/SUP], Han Bai[SUP] 4 [/SUP], Yixin Li[SUP] 1 4 [/SUP], Junpeng Ma[SUP] 1 [/SUP], Chengsheng Zhang[SUP] 5 6 [/SUP], Bingyin Shi[SUP] 7 [/SUP]
Affiliations
Background: The metabolomic profiles of individuals with different clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have not been clearly characterized.
Methods: We performed metabolomics analysis of 166 individuals, including 62 healthy controls, 16 individuals with asymptomatic SARS-CoV-2 infection, and 88 patients with moderate (n = 42) and severe (n = 46) symptomatic 2019 coronavirus disease (COVID-19; 17 with short-term and 34 with long-term nucleic-acid test positivity). By examining differential expression, we identified candidate metabolites associated with different SARS-CoV-2 infection presentations. Functional and machine learning analyses were performed to explore the metabolites' functions and verify their candidacy as biomarkers.
Results: A total of 417 metabolites were detected. We discovered 70 differentially expressed metabolites that may help differentiate asymptomatic infections from healthy controls and COVID-19 patients with different disease severity. Cyclamic acid and N-Acetylneuraminic Acid were identified to distinguish symptomatic infected patients and asymptomatic infected patients. Shikimic Acid, Glycyrrhetinic acid and 3-Hydroxybutyrate can supply significant insights for distinguishing short-term and long-term nucleic-acid test positivity.
Conclusion: Metabolomic profiling may highlight novel biomarkers for the identification of individuals with asymptomatic SARS-CoV-2 infection and further our understanding of the molecular pathogenesis of COVID-19.
Keywords: Asymptomatic infection; COVID-19; Long-term nucleic acid test positive; Metabolomics; SARS-CoV-2.
. 2024 Oct 28;21(1):266.
doi: 10.1186/s12985-024-02523-7. Metabolomic alterations in the plasma of patients with various clinical manifestations of COVID-19
Qi Xin[SUP] #[/SUP][SUP] 1 [/SUP], Xiao Liang[SUP] #[/SUP][SUP] 1 2 [/SUP], Jin Yang[SUP] 1 2 3 [/SUP], Xiaorui Wang[SUP] 1 [/SUP], Fang Hu[SUP] 1 [/SUP], Meng Jiang[SUP] 1 [/SUP], Yijia Liu[SUP] 1 [/SUP], Jin Gong[SUP] 1 2 [/SUP], Yiwen Pan[SUP] 1 [/SUP], Lijuan Liu[SUP] 1 [/SUP], Jiao Xu[SUP] 1 [/SUP], Yuxin Cui[SUP] 1 [/SUP], Hongyu Qin[SUP] 1 [/SUP], Han Bai[SUP] 4 [/SUP], Yixin Li[SUP] 1 4 [/SUP], Junpeng Ma[SUP] 1 [/SUP], Chengsheng Zhang[SUP] 5 6 [/SUP], Bingyin Shi[SUP] 7 [/SUP]
Affiliations
- PMID: 39468659
- PMCID: PMC11520427
- DOI: 10.1186/s12985-024-02523-7
Background: The metabolomic profiles of individuals with different clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have not been clearly characterized.
Methods: We performed metabolomics analysis of 166 individuals, including 62 healthy controls, 16 individuals with asymptomatic SARS-CoV-2 infection, and 88 patients with moderate (n = 42) and severe (n = 46) symptomatic 2019 coronavirus disease (COVID-19; 17 with short-term and 34 with long-term nucleic-acid test positivity). By examining differential expression, we identified candidate metabolites associated with different SARS-CoV-2 infection presentations. Functional and machine learning analyses were performed to explore the metabolites' functions and verify their candidacy as biomarkers.
Results: A total of 417 metabolites were detected. We discovered 70 differentially expressed metabolites that may help differentiate asymptomatic infections from healthy controls and COVID-19 patients with different disease severity. Cyclamic acid and N-Acetylneuraminic Acid were identified to distinguish symptomatic infected patients and asymptomatic infected patients. Shikimic Acid, Glycyrrhetinic acid and 3-Hydroxybutyrate can supply significant insights for distinguishing short-term and long-term nucleic-acid test positivity.
Conclusion: Metabolomic profiling may highlight novel biomarkers for the identification of individuals with asymptomatic SARS-CoV-2 infection and further our understanding of the molecular pathogenesis of COVID-19.
Keywords: Asymptomatic infection; COVID-19; Long-term nucleic acid test positive; Metabolomics; SARS-CoV-2.